Document Detail

Treatment of peripheral arterial disease using stem and progenitor cell therapy.
MedLine Citation:
PMID:  21030198     Owner:  NLM     Status:  MEDLINE    
Peripheral arterial disease (PAD) is a highly prevalent atherosclerotic syndrome associated with significant morbidity and mortality. PAD is most commonly caused by atherosclerosis obliterans (ASO) and thromboangiitis obliterans (TAO), and can lead to claudication and critical limb ischemia (CLI), often resulting in a need for major amputation and subsequent death. Standard treatment for such severe cases of PAD is surgical or endovascular revascularization. However, up to 30% of patients are not candidates for such interventions, due to high operative risk or unfavorable vascular involvement. Therefore, new strategies are needed to offer these patients a viable therapeutic option. Bone-marrow derived stem and progenitor cells have been identified as a potential new therapeutic option to induce angiogenesis. These findings prompted clinical researchers to explore the feasibility of cell therapies in patients with peripheral and coronary artery disease in several small trials. Clinical benefits were reported from these trials including improvement of ankle-brachial index (ABI), transcutaneous partial pressure of oxygen (TcO(2)), reduction of pain, and decreased need for amputation. Nonetheless, large randomized, placebo-controlled, double-blind studies are necessary and currently ongoing to provide stronger safety and efficacy data on cell therapy. Current literature is supportive of intramuscular bone marrow cell administration as a relatively safe, feasible, and possibly effective therapy for patients with PAD who are not subjects for conventional revascularization.
Holger Lawall; Peter Bramlage; Berthold Amann
Related Documents :
23953698 - Transition of mesenchymal stem/stromal cells to endothelial cells.
23729368 - Differential expression of p53 family proteins in colorectal adenomas and carcinomas: p...
17230218 - Stem cells transform into a cardiac phenotype with remodeling of the nuclear transport ...
22981438 - Sds3 interacts with arnt in an ahr ligand-specific manner regulating expression of ckro...
719188 - Dna repair deficiency in lymphocytes from patients with actinic keratosis.
22129888 - The characteristics and immunoregulatory functions of regulatory dendritic cells induce...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-10-27
Journal Detail:
Title:  Journal of vascular surgery     Volume:  53     ISSN:  1097-6809     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-31     Completed Date:  2011-03-10     Revised Date:  2012-10-03    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  445-53     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.
SRH-Klinikum Karlsbad-Langensteinbach, Angiology/Diabetology, Guttmannnstraβe 1, Karlsbad, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Collateral Circulation
Disease Models, Animal
Evidence-Based Medicine
Neovascularization, Physiologic*
Peripheral Arterial Disease / pathology,  physiopathology,  surgery*
Stem Cell Transplantation* / adverse effects,  methods
Transplantation, Autologous
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Iliac vein stenting in postmenopausal leg swelling.
Next Document:  Open abdominal aortic aneurysm repair is feasible and can be done with excellent results in octogena...